Am J Psychiatry 163:185-194, February 2006
doi: 10.1176/appi.ajp.163.2.185
© 2006 American Psychiatric Association
Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics
Stephan Heres, M.D.,
John Davis, M.D.,
Katja Maino, M.D.,
Elisabeth Jetzinger, M.D.,
Werner Kissling, M.D., and
Stefan Leucht, M.D.
OBJECTIVE: In many parts of the world, second-generation antipsychotics have largely replaced typical antipsychotics as the treatment of choice for schizophrenia. Consequently, trials comparing two drugs of this class—so-called head-to-head studies—are gaining in relevance. The authors reviewed results of head-to-head studies of second-generation antipsychotics funded by pharmaceutical companies to determine if a relationship existed between the sponsor of the trial and the drug favored in the study’s overall outcome. METHOD: The authors identified head-to-head comparison studies of second-generation antipsychotics through a MEDLINE search for the period from 1966 to September 2003 and identified additional head-to-head studies from selected conference proceedings for the period from 1999 to February 2004. The abstracts of all studies fully or partly funded by pharmaceutical companies were modified to mask the names and doses of the drugs used in the trial, and two physicians blinded to the study sponsor reviewed the abstracts and independently rated which drug was favored by the overall outcome measures. Two authors who were not blinded to the study sponsor reviewed the entire report of each study for sources of bias that could have affected the results in favor of the sponsor’s drug. RESULTS: Of the 42 reports identified by the authors, 33 were sponsored by a pharmaceutical company. In 90.0% of the studies, the reported overall outcome was in favor of the sponsor’s drug. This pattern resulted in contradictory conclusions across studies when the findings of studies of the same drugs but with different sponsors were compared. Potential sources of bias occurred in the areas of doses and dose escalation, study entry criteria and study populations, statistics and methods, and reporting of results and wording of findings. CONCLUSIONS: Some sources of bias may limit the validity of head-to-head comparison studies of second-generation antipsychotics. Because most of the sources of bias identified in this review were subtle rather than compelling, the clinical usefulness of future trials may benefit from minor modifications to help avoid bias. The authors make a number of concrete suggestions for ways in which potential sources of bias can be addressed by study initiators, peer reviewers of studies under consideration for publication, and readers of published studies.
This article has been cited by other articles:
|
|
|
|
 
J. P.A. Ioannidis
Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses
Can. Med. Assoc. J.,
October 13, 2009;
181(8):
488 - 493.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T Messer, T Glaser, H Landen, and M Schmauss
Long-term treatment with flupentixol results of a post-marketing surveillance study
J Psychopharmacol,
September 1, 2009;
23(7):
805 - 813.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Parks, A. Radke, G. Parker, M.-E. Foti, R. Eilers, M. Diamond, D. Svendsen, and R. Tandon
Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment
Schizophr Bull,
September 1, 2009;
35(5):
931 - 936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Greenland
Accounting for uncertainty about investigator bias: disclosure is informative: How could disclosure of interests work better in medicine, epidemiology and public health?
J Epidemiol Community Health,
August 1, 2009;
63(8):
593 - 598.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Davidson, S. Galderisi, M. Weiser, N. Werbeloff, W. W. Fleischhacker, R. S. Keefe, H. Boter, I. P.M. Keet, D. Prelipceanu, J. K. Rybakowski, et al.
Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST)
Am J Psychiatry,
June 1, 2009;
166(6):
675 - 682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Canuso, B. Dirks, J. Carothers, C. Kosik-Gonzalez, C. A. Bossie, Y. Zhu, C. V. Damaraju, A. H. Kalali, and R. Mahmoud
Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia
Am J Psychiatry,
June 1, 2009;
166(6):
691 - 701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Zink, A Kuwilsky, B Krumm, and H Dressing
Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial
J Psychopharmacol,
May 1, 2009;
23(3):
305 - 314.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Leucht, K. Komossa, C. Rummel-Kluge, C. Corves, H. Hunger, F. Schmid, C. Asenjo Lobos, S. Schwarz, and J. M. Davis
A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia
Am J Psychiatry,
February 1, 2009;
166(2):
152 - 163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Doucet and S Sismondo
Evaluating solutions to sponsorship bias
J. Med. Ethics,
August 1, 2008;
34(8):
627 - 630.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Maj
Non-financial conflicts of interests in psychiatric research and practice
The British Journal of Psychiatry,
August 1, 2008;
193(2):
91 - 92.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Scott
Cognitive-behavioural therapy for severe mental disorders: back to the future?
The British Journal of Psychiatry,
June 1, 2008;
192(6):
401 - 403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Shuchman MD and P. C. Hebert MD MHSc
Bringing a research base to psychiatry
Can. Med. Assoc. J.,
May 6, 2008;
178(10):
1257 - 1258.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Shuchman MD and P. C. Hebert MD MHSc
Etablir une base de recherche en psychiatrie
Can. Med. Assoc. J.,
May 6, 2008;
178(10):
1259 - 1260.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Swartz
Introduction to the CATIE Special Section
Psychiatr Serv,
May 1, 2008;
59(5):
497 - 499.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Domino and M. S. Swartz
Who Are the New Users of Antipsychotic Medications?
Psychiatr Serv,
May 1, 2008;
59(5):
507 - 514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Rosenheck, D. L. Leslie, and J. A. Doshi
Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making
Psychiatr Serv,
May 1, 2008;
59(5):
515 - 520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Parks, A. Q. Radke, and R. Tandon
Impact of the CATIE Findings on State Mental Health Policy
Psychiatr Serv,
May 1, 2008;
59(5):
534 - 536.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Salanti, F. K. Kavvoura, and J. P.A. Ioannidis
Exploring the Geometry of Treatment Networks
Ann Intern Med,
April 1, 2008;
148(7):
544 - 553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.A. Rosenheck, D.L. Leslie, S. Busch, E. S. Rofman, and M. Sernyak
Rethinking Antipsychotic Formulary Policy
Schizophr Bull,
March 1, 2008;
34(2):
375 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Leucht, S. Heres, J. Hamann, and J. M. Kane
Methodological Issues in Current Antipsychotic Drug Trials
Schizophr Bull,
March 1, 2008;
34(2):
275 - 285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. Stroup and J. R. Geddes
Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals
Schizophr Bull,
March 1, 2008;
34(2):
266 - 274.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Adams, E. S. F. Coutinho, J. Davis, L. Duggan, S. Leucht, C. Li, and P. Tharyan
Cochrane Schizophrenia Group
Schizophr Bull,
March 1, 2008;
34(2):
259 - 265.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Lewis and J. Lieberman
CATIE and CUtLASS: can we handle the truth?
The British Journal of Psychiatry,
March 1, 2008;
192(3):
161 - 163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Staller
Service Delivery in Child Psychiatry: Provider Shortage Isn't the Only Problem
Clinical Child Psychology and Psychiatry,
January 1, 2008;
13(1):
171 - 178.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. C. Owens
How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia
Adv. Psychiatr. Treat.,
January 1, 2008;
14(1):
17 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Goldberg, R. S. Goldman, K. E. Burdick, A. K. Malhotra, T. Lencz, R. C. Patel, M. G. Woerner, N. R. Schooler, J. M. Kane, and D. G. Robinson
Cognitive Improvement After Treatment With Second-Generation Antipsychotic Medications in First-Episode Schizophrenia: Is It a Practice Effect?
Arch Gen Psychiatry,
October 1, 2007;
64(10):
1115 - 1122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Rosenheck
Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics
The British Journal of Psychiatry,
September 1, 2007;
191(3):
238 - 245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Hodgson, C. Bushe, and R. Hunter
Measurement of long-term outcomes in observational and randomised controlled trials
The British Journal of Psychiatry,
August 1, 2007;
191(50):
s78 - s84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. E. Keefe, R. M. Bilder, S. M. Davis, P. D. Harvey, B. W. Palmer, J. M. Gold, H. Y. Meltzer, M. F. Green, G. Capuano, T. S. Stroup, et al.
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Arch Gen Psychiatry,
June 1, 2007;
64(6):
633 - 647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Heres, W. Kissling, S. Leucht, and for the Bias in Antipsychotic Studies workgroup
Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia
Evid. Based Ment. Health,
May 1, 2007;
10(2):
56 - 56.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Scherk, F. G. Pajonk, and S. Leucht
Second-Generation Antipsychotic Agents in the Treatment of Acute Mania: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Arch Gen Psychiatry,
April 1, 2007;
64(4):
442 - 455.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L Bettinger, G. Shuler, D. R Jones, and J. P Wilson
Schizophrenia: Multi-Attribute Utility Theory Approach to Selection of Atypical Antipsychotics
Ann. Pharmacother.,
February 1, 2007;
41(2):
201 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. ADAMS, P. THARYAN, E. S. F. COUTINHO, and T. S. STROUP
The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries
The British Journal of Psychiatry,
November 1, 2006;
189(5):
391 - 392.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Rosenheck
Outcomes, Costs, and Policy Caution: A Commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Arch Gen Psychiatry,
October 1, 2006;
63(10):
1074 - 1076.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Freedman, D. A. Lewis, R. Michels, D. S. Pine, S. K. Schultz, C. Tamminga, S. L. Patterson, J. S. Mcintyre, H. H. Goldman, S. C. Yudofsky, et al.
Conflict of Interest, Round 2
Am J Psychiatry,
September 1, 2006;
163(9):
1481 - 1483.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. TANDON
Comparing Antipsychotic Efficacy
Am J Psychiatry,
September 1, 2006;
163(9):
1645 - 1645.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Tandon and H. A. Nasrallah
Subjecting Meta-analyses to Closer Scrutiny: Little Support for Differential Efficacy Among Second-Generation Antipsychotics at Equivalent Doses.
Arch Gen Psychiatry,
August 1, 2006;
63(8):
935 - 937.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Chalmers
From optimism to disillusion about commitment to transparency in the medico-industrial complex
J R Soc Med,
July 1, 2006;
99(7):
337 - 341.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Reviews of Note
Journal Watch Psychiatry,
March 22, 2006;
2006(322):
8 - 8.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2006
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
